EUVIMEDEUVIMED entdecken
Crossref

Impact of pituitary adenoma histological subtype on remission and disease control in acromegaly

Alexandra Monnot iD, Mirela-Diana Ilie iD, Camille Sergeant iD, Alexandre Vasiljevic iD, Sihem Zaghdoud, Emmanuel Jouanneau iD, Gérald Raverot iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Alexandra Monnot und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron 69677, France. Hauptthemen laut MEDLINE: Acromegaly, Adenoma, Growth Hormone-Secreting Pituitary Adenoma, Pituitary Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Bibliothèque Scientifique de l'Internat de Lyon and the Hospices Civils de Lyon, Bibliothèque Scientifique de l’Internat de Lyon and the Hospices Civils de Lyon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acromegaly results from different histological subtypes of pituitary adenomas, mainly pure GH-secreting adenomas (densely or sparsely granulated) and GH-PRL adenomas. Data on the impact of histological subtype on surgical outcomes in acromegaly remain limited.

Objectives

This study aimed to assess the impact of pituitary adenoma histological subtype on acromegaly remission at 3 months and last follow-up, as well as on disease control.

Methods

We conducted a retrospective, single-center study of 128 patients who underwent surgery for GH or GH-PRL adenomas, without prior medical therapy, between 2012 and 2022.

Results

Among the adenomas, 61% were pure GH (39% DG, 22% SG) and 39% were GH-PRL. Compared with DG adenomas, SG adenomas were diagnosed at a younger age (P = .006), were larger (P = .022), expressed more SST5 (P = .032) and less SST2 (P < .001). GH-PRL adenomas were more frequently p53-positive (P = .024), had a higher mitotic count (P = .017) than DG adenomas and expressed more SST2 than SG adenomas (P < .001). The remission rates for DG, GH-PRL and SG adenomas were not significantly different at 3 months (60%, 58% and 43%, P = .337), or at last follow-up (80%, 74% and 57%, P = .091), nor was disease control at last follow-up (94%, 96% and 82%, P = .115) after 42 months.

Conclusion

Histological subtype was not significantly associated with remission or control of acromegaly. Although a trend toward lower remission rates was observed in SG adenomas, its clinical impact appears limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyAdenomaGrowth Hormone-Secreting Pituitary AdenomaPituitary NeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultRemission InductionFollow-Up StudiesAgedTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

acromegalydensely granulatedprolactinsomatotroph adenomasparsely granulatedsurgical remission

Autor:innen und Institutionen

  • Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron 69677, France.
  • Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, Lyon 69008, France.
  • Endocrinology Department, C.I. Parhon National Institute of Endocrinology, Bucharest 011863, Romania.
  • Pathology Department, Reference Center for Rare Pituitary Diseases HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron 69677, France.
  • Neurosurgery Department, Reference Center for Rare Pituitary Diseases HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron 69677, France.

ORCID-Profile: Alexandra Monnot, Mirela-Diana Ilie, Camille Sergeant, Alexandre Vasiljevic, Emmanuel Jouanneau, Gérald Raverot

Förderung

  • Bibliothèque Scientifique de l'Internat de Lyon and the Hospices Civils de Lyon
  • Bibliothèque Scientifique de l’Internat de Lyon and the Hospices Civils de Lyon

Zitieren

APA

Monnot, A., Ilie, M. D., Sergeant, C., Vasiljevic, A., Zaghdoud, S., Jouanneau, E., & Raverot, G. (2026). Impact of pituitary adenoma histological subtype on remission and disease control in acromegaly. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag174

Vancouver

Monnot A, Ilie MD, Sergeant C, Vasiljevic A, Zaghdoud S, Jouanneau E, et al. Impact of pituitary adenoma histological subtype on remission and disease control in acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag174

BibTeX
@article{Monnot2026,
  author = {Monnot, Alexandra and Ilie, Mirela-Diana and Sergeant, Camille and Vasiljevic, Alexandre and Zaghdoud, Sihem and Jouanneau, Emmanuel and Raverot, Gérald},
  title = {Impact of pituitary adenoma histological subtype on remission and disease control in acromegaly},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag174}
}
Kostenlos starten →